← NEOGENOMICS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $244.1m |
$258.6m
+5.95%
|
$276.7m
+7.01%
|
$408.8m
+47.73%
|
$444.4m
+8.71%
|
$484.3m
+8.97%
|
$509.7m
+5.24%
|
$591.6m
+16.07%
|
$660.6m
+11.65%
|
$727.3m
+10.11%
|
$766.3m
+5.36%
|
|
| Cost of Revenue | $133.7m |
$138.3m
+3.43%
|
$149.5m
+8.08%
|
$212.0m
+41.82%
|
$258.6m
+21.96%
|
$297.3m
+14.97%
|
$321.8m
+8.26%
|
$347.0m
+7.83%
|
$370.5m
+6.75%
|
$413.0m
+11.49%
|
$429.8m
+4.05%
|
|
| Gross Profit | $110.4m |
$120.3m
+9.00%
|
$127.3m
+5.78%
|
$196.8m
+54.67%
|
$185.9m
-5.56%
|
$187.1m
+0.63%
|
$187.9m
+0.45%
|
$244.6m
+30.18%
|
$290.1m
+18.60%
|
$314.3m
+8.34%
|
$336.5m
+7.08%
|
|
| Research and Development Expense | $4.6m | $3.6m | $3.0m | $8.5m | $8.2m | $21.9m | $30.3m | $27.3m | $31.2m | $37.1m | $38.2m | |
| Selling and Marketing Expense | $23.9m | $24.5m | $29.4m | $47.4m | $47.9m | $62.6m | $67.3m | $70.8m | $84.7m | $92.0m | $325.4m | |
| General and Administrative Expense | $75.8m | $88.8m | $84.8m | $128.0m | $143.8m | $221.3m | $243.4m | $243.1m | $259.7m | $273.3m | $229.1m | |
| Amortization of Intangible Assets | $7.3m | $7.0m | $5.9m | $9.9m | $9.8m | $23.2m | $34.1m | $35.1m | $33.4m | $31.8m | — | |
| Operating Lease, Expense | — | — | — | $5.6m | $6.2m | $8.7m | $9.8m | $9.2m | $8.9m | $6.8m | — | |
| Restructuring and Related Cost, Incurred Cost | — | — | — | — | — | — | $3.8m | — | — | — | — | |
| Operating Expenses | $107.8m | $118.0m | $117.2m | $183.8m | $199.9m | $305.8m | $345.5m | $352.3m | $382.2m | $430.2m | $397.3m | |
| Operating Income (Loss) | $2.6m |
$2.3m
-9.71%
|
$10.0m
+332.01%
|
$13.0m
+29.54%
|
($14.0m)
-207.58%
|
($118.8m)
-748.73%
|
($157.6m)
-32.73%
|
($107.7m)
+31.65%
|
($92.1m)
+14.51%
|
($115.9m)
-25.81%
|
($60.7m)
+47.59%
|
|
| Interest Income, Operating | — | — | — | — | — | — | — | $16.9m | — | — | $5.6m | |
| Investment Income, Interest | — | — | — | — | — | — | — | — | $18.4m | $9.1m | — | |
| Other Nonoperating Income (Expense) | — | ($265k) | $14k | ($4.6m) | $11.9m | ($499k) | ($213k) | $644k | ($379k) | $296k | — | |
| Interest Expense (non-operating) | — | — | — | $3.7m | $7.0m | $5.1m | $1.5m | $6.9m | $6.6m | $3.8m | $2.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($7.4m) | ($3.5m) | $3.8m | $3.6m | ($14.1m) | ($15.1m) | ($159.3m) | ($97.1m) | ($80.7m) | ($110.3m) | ($54.5m) | |
| Current Income Tax Expense (Benefit) | $31k | ($77k) | ($322k) | ($13k) | ($161k) | $82k | $152k | $391k | $625k | $866k | ($2.7m) | |
| Income Tax Expense (Benefit) | ($1.7m) | ($2.6m) | $1.2m | ($4.4m) | ($18.2m) | ($6.7m) | ($15.1m) | ($9.1m) | ($1.9m) | ($2.2m) | ($2.7m) | |
| Net Income (Loss) Attributable to Parent | ($5.7m) |
($846k)
+85.22%
|
$2.6m
+412.06%
|
$8.0m
+203.26%
|
$4.2m
-47.89%
|
($8.3m)
-300.07%
|
($144.2m)
-1628.17%
|
($88.0m)
+39.02%
|
($78.7m)
+10.51%
|
($108.0m)
-37.22%
|
($51.9m)
+51.98%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($30.4m) |
($11.4m)
+62.52%
|
$6.1m
+153.44%
|
$8.0m
+31.50%
|
$4.2m
-47.89%
|
($8.3m)
-300.07%
|
($144.2m)
-1628.17%
|
($88.0m)
+39.02%
|
($78.7m)
+10.51%
|
— | ($51.9m) | |
| Income (Loss) from Continuing Operations, Per Basic Share | ($0) | ($0) | $0 | $0 | $0 | ($0) | ($1) | ($1) | ($1) | ($1) | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | ($0) | ($0) | $0 | $0 | $0 | ($0) | ($1) | ($1) | ($1) | ($1) | — | |
| Weighted Average Number of Shares Outstanding, Basic | 77.5m | 79.4m | 85.6m | 100.5m | 108.6m | 120.0m | 124.2m | 125.5m | 126.7m | 128.1m | 129.0m | |
| Weighted Average Number of Shares Outstanding, Diluted | 77.5m | 79.4m | 91.6m | 103.6m | 111.8m | 120.0m | 124.2m | 125.5m | 126.7m | 128.1m | 129.0m | |
| Additional Financial Items | ||||||||||||
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | $0 | $0 | $3.5m | $7.7m |